Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418).

Author(s): Chiou Victoria L.,  Kohn Elise C.,  Annunziata Christina M.,  Minasian Lori M.,  Lipkowitz Stan,  Yu Minshu,  Gordon Nicolas,  Houston Nicole D.,  Lee Jung-min

Journal: J Clin Oncol

Date: 2015 May 20

Major Program(s) or Research Group(s): OD

PubMed ID:

PMC ID: not available